How Shefferman was paid
$2.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Jesse SheffermanPresident, Chief Executive Officer and Director | $654,888 | — | $294,450 | $1,277,216 | $351,184 | $78,036 | $2,655,774 |
| Leonardo Nicacio, M.D.Chief Medical Officer | $373,864 | $75,000 | $208,500 | $453,435 | $229,753 | $41,931 | $1,382,483 |
| Jacqueline Zummo, Ph.D.Chief R&D Officer | $494,000 | — | $110,985 | $481,844 | $219,521 | $75,924 | $1,382,274 |
What changed and why
- $2.7MCEO total compensation increased to $2,655,774 in 2025 from $1,791,843 in 2024.
- $655KMr. Shefferman received a base salary of $654,888 and non-equity incentive plan compensation of $351,184.
- 97.5%The board approved a 97.5% overall achievement level for 2025 corporate goals.
- $294KEquity awards for the CEO included $294,450 in stock awards and $1,277,216 in option awards.
- $75,000Dr. Nicacio received a one-time signing bonus of $75,000 upon joining the company in April 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.